January 2016

Eli Lilly's President & CEO: Toronto, Indianapolis, and the Breakthrough that Saved Millions of Lives

11:45am-1:30pm | The Hilton Toronto - 145 Richmond St. W., Toronto

The discovery, testing, and mass-production of insulin in the early 1920s—linking scientists at the University of Toronto with Eli Lilly and Company in Indianapolis—is an epic but neglected story of collaboration against a killer disease. Dr. Lechleiter will argue that it provides essential insights for today’s efforts to overcome the chronic diseases—especially Alzheimer’s disease, cancer, and the continuing ravages of diabetes—that threaten to harm every family and overwhelm every public and private budget in our nations.
As a scientist himself and one of the longest-serving leaders in the global pharmaceuticals arena, Dr. Lechleiter brings unique experience and passion to the questions of what industry, academia, private citizens, and government can do to assure future triumphs against disease. He believes that governments must sustain the incentives that drive innovation—and that the discovery and development of medicines hinge on global collaboration, trust, and openness across sectors.

Member price:
Individual seat: $89 +HST
Table (seats 10): $800 +HST

Regular price:
Individual seat: $110 +HST
Table (seats 10): $990 +HST

*Speech at 12 p.m., lunch to follow*

Eli Lilly's President & CEO: Toronto, Indianapolis, and the Breakthrough that Saved Millions of Lives

John C. Lechleiter, Ph.D

Chairman, President, and Chief Executive Officer
Eli Lilly

John C. Lechleiter, Ph.D

John Lechleiter has served as president and chief executive officer of Eli Lilly and Company since April 1, 2008. He became chairman of the board of directors on January 1, 2009.

John joined Lilly in 1979 as a senior organic chemist in process research and development and became head of that department in 1982. In 1984, he began serving as director of pharmaceutical product development for the Lilly Research Centre Limited in Windlesham, England. He later held roles in project management, regulatory affairs, product development, and pharma operations. In 2005, he was named president and chief operating officer and joined the board of directors.

John earned a bachelor’s degree in chemistry from Xavier University and master’s and doctoral degrees in organic chemistry from Harvard University. John has received honorary doctorates from Marian University (Indianapolis, Indiana), the University of Indianapolis, the National University of Ireland, Indiana University, and Franklin College.

John is a member of the American Chemical Society. He serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA), as chairman of the U.S.-Japan Business Council and of United Way Worldwide, and on the boards of the Chemical Heritage Foundation and the Central Indiana Corporate Partnership. He also serves on the boards of Nike, Inc. and Ford Motor Company.

Our Sponsors

Telus Interac Green Shield Canada